BRIEF-Alnylam Pharma Announces New Positive Interim Phase 1 Study Results for Fitusiran
July 25, 2016 at 13:55 PM EDT
* Company updates guidance for phase 3, and now plans to start studies in early 2017
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.